A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Latest Information Update: 23 Dec 2022
At a glance
- Drugs Cyclophosphamide (Primary) ; Durvalumab (Primary) ; ONCOS 102 (Primary)
- Indications Appendiceal cancer; Carcinoma; Colorectal cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 15 Nov 2021 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.